{"filing":{"accession_number":"0001140361-26-031502","cik":"0001104506","ticker":"INSM","company_name":"INSMED Inc","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ef20079469_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_8k.htm"},"events":[{"id":25452,"run_id":23104,"accession_number":"0001140361-26-031502","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The filing discloses total company revenues of $425.5 million, product-specific revenues (BRINSUPRI $309.2M, ARIKAYCE $116.3M), operating expenses, net loss of $13.2 million, and balance sheet information. The company also raised full-year 2026 BRINSUPRI revenue guidance to $1.25-$1.40 billion and raised peak revenue estimates for its three lead programs to more than $14 billion combined. This is a material disclosure affecting investor assessment of the registrant's financial performance and outlook.","company_name":"INSMED Inc","ticker":"INSM","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26285,"accession_number":"0001140361-26-031502","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The filing discloses total company revenues of $425.5 million, product-specific revenues (BRINSUPRI $309.2M, ARIKAYCE $116.3M), operating expenses, net loss of $13.2 million, and balance sheet information. The company also raised full-year 2026 BRINSUPRI revenue guidance to $1.25-$1.40 billion and raised peak revenue estimates for its three lead programs to more than $14 billion combined. This is a material disclosure affecting investor assessment of the registrant's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:03.954286+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26285,"accession_number":"0001140361-26-031502","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The filing discloses total company revenues of $425.5 million, product-specific revenues (BRINSUPRI $309.2M, ARIKAYCE $116.3M), operating expenses, net loss of $13.2 million, and balance sheet information. The company also raised full-year 2026 BRINSUPRI revenue guidance to $1.25-$1.40 billion and raised peak revenue estimates for its three lead programs to more than $14 billion combined. This is a material disclosure affecting investor assessment of the registrant's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:03.954286+00:00","company_name":"INSMED Inc","ticker":"INSM","filing_date":"2026-08-06"}]}